203 related articles for article (PubMed ID: 21768793)
41. Therapeutic significance of a D-dimer cut-off level of >3 µg/ml in colorectal cancer patients treated with standard chemotherapy plus bevacizumab.
Mochizuki S; Yoshino T; Kojima T; Fuse N; Ikematsu H; Minashi K; Yano T; Tahara M; Kaneko K; Doi T; Koike K; Ohtsu A
Jpn J Clin Oncol; 2010 Oct; 40(10):933-7. PubMed ID: 20494948
[TBL] [Abstract][Full Text] [Related]
42. Role of CA19.9 in predicting bevacizumab efficacy for metastatic colorectal cancer patients.
Formica V; Massara MC; Portarena I; Fiaschetti V; Grenga I; Del Vecchio Blanco G; Sileri P; Tosetto L; Skoulidis F; Pallone F; Roselli M
Cancer Biomark; 2009; 5(4):167-75. PubMed ID: 19729826
[TBL] [Abstract][Full Text] [Related]
43. Impact of stereotactic body radiotherapy on colorectal cancer with distant metastases.
Hiraki M; Nishimura J; Ohtsuka M; Shiomi H; Uemura M; Haraguchi N; Hata T; Hayashi T; Takemasa I; Mizushima T; Isohashi F; Yoshioka Y; Ogawa K; Doki Y; Mori M; Yamamoto H
Oncol Rep; 2014 Feb; 31(2):795-9. PubMed ID: 24284831
[TBL] [Abstract][Full Text] [Related]
44. Current stages of adjuvant treatment of colon cancer.
Köhne CH
Ann Oncol; 2012 Sep; 23 Suppl 10():x71-6. PubMed ID: 22987996
[No Abstract] [Full Text] [Related]
45. [A case of advanced colon cancer with peritoneal dissemination effectively treated with modified FOLFOX6 chemotherapy].
Tanaka K; Hirai K; Ogawa H; Toya H; Totsuka O; Yoshinari D; Sunose Y; Takeyoshi I
Gan To Kagaku Ryoho; 2012 Jun; 39(6):993-5. PubMed ID: 22705700
[TBL] [Abstract][Full Text] [Related]
46. [A recurrence after surgery for colon cancer with metastases of the liver and periaortic lymph nodes, with CR achieved by using bevacizumab+mFOLFOX6].
Matsukawa S; Shiratori T; Kugimiya M; Matsuo S; Kaji S; Aoyama Y
Gan To Kagaku Ryoho; 2010 Jul; 37(7):1389-91. PubMed ID: 20647734
[TBL] [Abstract][Full Text] [Related]
47. [Evaluation of bevacizumab for advanced colorectal cancer].
Naito M; Hoshino S; Noda N; Nakano M; Matsuo K; Yamauchi Y; Shinohara T; Tanaka S; Yamashita Y
Gan To Kagaku Ryoho; 2010 Jan; 37(1):83-8. PubMed ID: 20087037
[TBL] [Abstract][Full Text] [Related]
48. Clinical and economic evaluation of first-line therapy with FOLFIRI or modified FOLFOX6 for metastatic colorectal cancer.
Ajima H; Ogata H; Fujita K; Miwa K; Sunakawa Y; Mizuno K; Ishida H; Yamashita K; Nakayama H; Kawara K; Takahashi H; Sasaki Y
Jpn J Clin Oncol; 2010 Jul; 40(7):634-8. PubMed ID: 20587616
[TBL] [Abstract][Full Text] [Related]
49. [A case of liver metastases from rectal cancer showed a complete response by FOLFIRI and bevacizumab chemotherapy].
Kuwada A; Nakamitsu A; Imamura Y; Kouyama M; Uekami S; Touge K; Taogoshi H; Fukuda Y; Daimaru H
Gan To Kagaku Ryoho; 2010 Dec; 37(13):2937-40. PubMed ID: 21160275
[TBL] [Abstract][Full Text] [Related]
50. [A case of undifferentiated colon cancer responding to FOLFIRI therapy].
Fujiwara K; Nagayoshi Y; Nakahara C; Yamasaki T; Iwashita T
Gan To Kagaku Ryoho; 2011 Sep; 38(9):1525-7. PubMed ID: 21918355
[TBL] [Abstract][Full Text] [Related]
51. Chemotherapy of metastatic colorectal cancer: fluorouracil plus folinic acid and irinotecan or oxaliplatin.
Prescrire Int; 2005 Dec; 14(80):230-3. PubMed ID: 16400749
[TBL] [Abstract][Full Text] [Related]
52. Reversible posterior leukoencephalopathy syndrome after bevacizumab/FOLFIRI regimen for metastatic colon cancer.
Allen JA; Adlakha A; Bergethon PR
Arch Neurol; 2006 Oct; 63(10):1475-8. PubMed ID: 17030665
[TBL] [Abstract][Full Text] [Related]
53. [A case of colon cancer with multiple liver metastases responding ot S-1 as third-line treatment following FOLFIRI and FOLFOX].
Miyahira T; Teruya N; Matsuura F; Murayama S; Aka H; Teruya J; Hanashiro N; Nishihara M; Okushima N; Toda Y; Kiyuna M
Gan To Kagaku Ryoho; 2010 Feb; 37(2):331-4. PubMed ID: 20210032
[TBL] [Abstract][Full Text] [Related]
54. [Efficacy and safety of antivascular drugs after anti-EFGR: aflibercept after cetuximab, a clinical case].
Aroldi F; Zaniboni A
Recenti Prog Med; 2015 Dec; 106(12):653e-6e. PubMed ID: 26780078
[TBL] [Abstract][Full Text] [Related]
55. [A case of interstitial pneumonitis induced by FOLFIRI+bevacizumab combination therapy for liver and lung metastasis of colon cancer].
Tamura J; Nakauchi M; Nakayama Y; Kitaguchi K; Sakikubo M; Ura K; Taira K; Ohe H; Yoshikawa A; Ishigami S; Baba N
Gan To Kagaku Ryoho; 2009 Dec; 36(13):2665-8. PubMed ID: 20009477
[TBL] [Abstract][Full Text] [Related]
56. [A Case of Liver Metastasis of Descending Colon Cancer with a Pathological Complete Response to mFOLFOX6].
Kawamoto Y; Ome Y; Koda Y; Saga K; Kawamoto K; Ito T
Gan To Kagaku Ryoho; 2016 Jan; 43(1):125-8. PubMed ID: 26809540
[TBL] [Abstract][Full Text] [Related]
57. [A case of irinotecan or panitumumab-induced interstitial pneumonia successfully treated by steroid pulse therapy].
Yamamoto K; Kato T; Shindo J; Ando M; Abe T; Shiraki A; Nakashima H; Yukita Y
Gan To Kagaku Ryoho; 2012 Feb; 39(2):305-9. PubMed ID: 22333650
[TBL] [Abstract][Full Text] [Related]
58. [A case of liver metastasis of rectal cancer, refractory to previous chemotherapy(5-FU/LV, irinotecan, oxaliplatin) responding to bevacizumab combined with FOLFIRI chemotherapy].
Nishigami K; Kawami H; Yamaguchi T; Yamaguchi K; Kato S
Gan To Kagaku Ryoho; 2009 Oct; 36(10):1765-8. PubMed ID: 19838045
[TBL] [Abstract][Full Text] [Related]
59. NCCN guideline updates: colon and rectal cancers, version 1.2004.
National Comprehensive Cancer Network
J Natl Compr Canc Netw; 2004 Jul; 2(4):284-5. PubMed ID: 19795595
[No Abstract] [Full Text] [Related]
60. [Late complete response after long remission from treatment with FOLFIRI-aflibercept for metastatic colorectal cancer after progression to FOLFOX-bevacizumab].
De Divitiis C; Cassata A; Nasti G; Ottaiano A; Nappi A; Barretta ML; Iaffaioli RV
Recenti Prog Med; 2015 Aug; 106(8):e407-13. PubMed ID: 26228865
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
